Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer
- 1 February 2006
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 100 (2), 344-348
- https://doi.org/10.1016/j.ygyno.2005.08.036
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective studyGynecologic Oncology, 2003
- Future directions in the surgical management of ovarian cancerGynecologic Oncology, 2003
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-AnalysisJournal of Clinical Oncology, 2002
- The Effect of Bowel Resection on Survival in Advanced Epithelial Ovarian CancerGynecologic Oncology, 2001
- A Critique of Surgical Cytoreduction in Advanced Ovarian CancerGynecologic Oncology, 2000
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- The Prognostic Significance of Residual Disease, FIGO Substage, Tumor Histology, and Grade in Patients with FIGO Stage III Ovarian CancerGynecologic Oncology, 1995
- The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology, 1992
- Primary surgical therapy of ovarian cancer: How much and whenGynecologic Oncology, 1990
- Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1989